You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Adjusted odds ratiosa (aORs) and 95% confidence intervals (CIs) for prescribing vs. not prescribing a drug based on receiving any payment vs. no paymentb

From: Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

 Drug of Uncertain Medical Benefit aOR (95%CI) Brand Control aOR (95%CI) Generic Control aOR (95%CI)
Lovastatin ER 1.28 (0.82–2.80) Rosuvastatin 1.80 (1.74–1.86) Lovastatin 0.78 (0.76–0.80)
Almotriptan 1.36 (0.83–2.23) Rizatriptan 0.93 (0.68–1.27) Sumatriptan 0.74 (0.50–1.10)
Amlodipine+olmesartan 1.42 (1.36–1.49) Telmisartan 1.18 (1.08–1.29) Irbesartan 0.74 (0.70–0.78)
Ibuprofen+famotidine 1.10 (0.76–1.60) Celecoxib 1.85 (1.80–1.89) Ibuprofen 0.79 (0.77–0.81)
Saxagliptin+metformin 1.50 (1.42–1.59) Sitagliptin 1.45 (1.42–1.48) Metformin 0.80 (0.72–0.89)
Naproxen+esomeprazole 1.45 (1.25–1.68) Celecoxib 1.61 (1.57–1.65) Naproxen 0.74 (0.72–0.76)
  1. aAdjusted for gender, specialty, region, therapeutic category and overall prescribing volume
  2. bEach drug was analyzed in a separate model
  3. p-value <0.05 are presented in boldface